Joi Dunbar
Overview
Explore the profile of Joi Dunbar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dunbar J, Walling D, Hassman H, Jain R, Czysz A, Nandy I, et al.
J Psychopharmacol
. 2024 Oct;
38(12):1122-1136.
PMID: 39394685
Background: Zuranolone is an oral, once-daily, 14-day treatment course approved for adults with postpartum depression in the United States. Aims: To assess cognitive effects, pharmacokinetics, and safety of zuranolone, alone...
2.
Dunbar J, Morelli G, Jain R, Vaudreuil C, Nandy I, Ona V, et al.
Psychopharmacology (Berl)
. 2024 Sep;
242(2):389-400.
PMID: 39302437
Rationale: Zuranolone is an oral positive allosteric modulator of GABA receptors. Due to its central nervous system (CNS) activity, zuranolone may impact activities requiring complex cognition, including driving. Objective: Evaluate...
3.
Deligiannidis K, Bullock A, Nandy I, Dunbar J, Lasser R, Witte M, et al.
J Clin Psychopharmacol
. 2024 May;
44(4):337-344.
PMID: 38739007
Purpose/background: Zuranolone is a positive allosteric modulator of both synaptic and extrasynaptic γ-aminobutyric acid type A receptors and a neuroactive steroid approved as an oral, once-daily, 14-day treatment course for...
4.
Dunbar J, Versavel M, Zhao Y, Tate S, Morisset V, Giblin G, et al.
Clin Pharmacol Drug Dev
. 2019 Oct;
9(1):62-73.
PMID: 31650711
Vixotrigine is a voltage- and use-dependent Nav1.7 channel blocker under investigation for the treatment of peripheral neuropathic pain conditions, including trigeminal neuralgia. Vixotrigine is metabolized primarily via uridine diphosphate-glucuronosyltransferases (UGTs)....
5.
Wagner A, Chugh R, Rosen L, Morgan J, George S, Gordon M, et al.
Clin Cancer Res
. 2013 Sep;
19(21):6020-9.
PMID: 24045182
Purpose: Heat shock protein 90 (HSP90) is required for the proper folding, function, and stability of various client proteins, two of which (KIT and PDGFRα) are critical in the pathogenesis...
6.
Jimeno A, Weiss G, Miller Jr W, Gettinger S, Eigl B, Chang A, et al.
Clin Cancer Res
. 2013 Apr;
19(10):2766-74.
PMID: 23575478
Purpose: To conduct a first-in-human phase I study to determine the dose-limiting toxicities (DLT), characterize the pharmacokinetic profile, and document the antitumor activity of IPI-926, a new chemical entity that...
7.
Smith S, Hoyt J, Whitebread N, Manna J, Peluso M, Faia K, et al.
Xenobiotica
. 2013 Mar;
43(10):875-85.
PMID: 23527529
1. IPI-926 is a novel semisynthetic cyclopamine derivative that is a potent and selective Smoothened inhibitor that blocks the hedgehog signal transduction pathway. 2. The in vivo clearance of IPI-926...
8.
Siegel D, Jagannath S, Vesole D, Borello I, Mazumder A, Mitsiades C, et al.
Leuk Lymphoma
. 2011 Aug;
52(12):2308-15.
PMID: 21851215
Abstract A phase 1 study of IPI-504 (retaspimycin hydrochloride) administered intravenously twice weekly for 2 weeks at 22.5, 45, 90, 150, 225, 300 or 400 mg/m(2) followed by 10 days...
9.
Oh W, Galsky M, Stadler W, Srinivas S, Chu F, Bubley G, et al.
Urology
. 2011 Jul;
78(3):626-30.
PMID: 21762967
Objective: To evaluate clinical activity and safety of retaspimycin hydrochloride (IPI-504) in patients with castration-resistant prostate cancer (CRPC). Methods: A single-arm trial was conducted in 2 cohorts: group 1, chemotherapy...